Stock CASI CASI PHARMACEUTICALS, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Highlights CASI Pharmaceuticals, Inc.

Equities

CASI

KYG1933S1012

Market Closed - Nasdaq
Other stock markets
 02:00:00 09/05/2024 am IST 		5-day change 1st Jan Change
2.64 USD +1.15% Intraday chart for CASI Pharmaceuticals, Inc. +10.46% -63.13%
28/03 CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
05/03 Top Midday Gainers MT

Highlights

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Rate Cut Uncertainty Pushes Exchange-Traded Funds, Equity Futures Lower Pre-Bell Tuesday
MT
CASI Pharmaceuticals Report Positive Interim Phase 1 Data for BI-1206 in the Treatment of Relapsed/Refractory Indolent Non-Hodgkin's Lymphoma in China
CI
CASI Pharmaceuticals, Inc. and CASI Pharmaceuticals Co. Ltd Enter into Certain Agreement with Respect to the Renewal of the Exclusive Distribution Agreement with China Resources Pharmaceutical Commercial Group International Trading Co., Ltd
CI
Casi Pharmaceuticals Announces First Dose of Folotyn in China
CI
CASI Pharmaceuticals, Inc. Enters into an Exclusive Distribution Agreement with China National Medicines Corporation Ltd
CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q3 Revenue $8.8M
MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Posts Q2 Revenue $9.8M
MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
CASI Pharmaceuticals Acquires Intellectual Property Rights to Cleave Therapeutics' Drug Candidate CB-5339
MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q1 Revenue $8.3M
MT
CASI Pharmaceuticals, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022
CI
Earnings Flash (CASI) CASI PHARMACEUTICALS Reports Q4 Revenue $43.1M
MT
North American Morning Briefing : Focus Turns to -2-
DJ
CASI Pharmaceuticals Completes Redomiciliation Merger
MT
CASI PHARMACEUTICALS COMPLETES REDOMICILIATION MERGER
PR
CASI, Cleave Say China Drug Regulator Approves Clinical Trial Application for CB-5339 in Patients With Multiple Myeloma
MT
CASI Pharmaceuticals, Inc. Announces Clinical Trial Application Approval for CB-5339 in Patients with Multiple Myeloma in China
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. CASI Stock
  4. News CASI Pharmaceuticals, Inc.
  5. Highlights
-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW